Welcome to our dedicated page for Anteris Technologies Global SEC filings (Ticker: AVR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Anteris Technologies Global Corp. filings document the regulatory record of a structural heart medical device issuer developing the DurAVR® Transcatheter Heart Valve for aortic stenosis. Its reports and material-event filings cover operating and financial results, Form 10-K disclosures, clinical and regulatory activity tied to the PARADIGM trial, research and development spending, risk factors and management discussion of liquidity and operations.
The company’s SEC filings also describe material agreements, facility leases, strategic investment and public offering activity, common-stock capital structure, registration statements, equity incentive awards, director and officer governance matters, subsidiary arrangements and disclosures furnished for ASX reporting. These documents connect AVR’s device-development program with financing, governance and public-company reporting obligations.
Anteris Technologies Global Corp. reported weaker 2025 financial results alongside a strategic update on its DurAVR® transcatheter heart valve program. Revenue from ordinary activities was US$1.9 million in 2025, down from US$2.7 million in 2024, a 29% decline as the company focused on clinical development.
The loss from ordinary activities after tax increased to US$94.2 million from US$76.0 million, and loss attributable to members rose to US$94.1 million. Net tangible asset backing per share deteriorated from US$1.74 to (US$0.01) as of December 31, 2025, reflecting accumulated losses. Net operating cash outflows were US$77.8 million, in line with higher clinical, regulatory and manufacturing spend to support its pivotal Trial. The company confirmed that all US$80.0 million of net IPO proceeds raised in December 2024 have been fully used, paid no dividends, and saw no material impact from deregistering two Australian subsidiaries. The Trial has begun enrolling and implanting patients, targeting about 1,000 participants in a head‑to‑head study versus existing TAVR valves.
Anteris Technologies Global Corp. files its annual report describing a development-stage structural heart company focused on the DurAVR® transcatheter heart valve (THV) system for aortic stenosis. DurAVR® combines a single-piece biomimetic valve made from proprietary ADAPT® anti-calcification tissue with the ComASUR® balloon-expandable delivery system.
More than 130 patients have received DurAVR® worldwide through first-in-human, early feasibility and compassionate-use cases, showing favorable hemodynamics and high technical success in small aortic annuli. In 2025, Anteris began a global randomized pivotal Trial comparing DurAVR® to approved TAVR devices, enrolling first patients in Denmark after European approval and securing a staged FDA IDE for the first 200 U.S. patients.
The company targets a growing TAVR market that FMI estimates could reach $9.9 billion for severe aortic stenosis and $2.5 billion for valve-in-valve procedures by 2028, with North America and Europe as core regions. Anteris remains loss-making, relies on single-source suppliers and development partners, holds 47 active patents and 75 pending applications as of December 31, 2025, and faces extensive clinical, regulatory, financing and competitive risks highlighted in its risk factor summary.
Anteris Technologies Global Corp. received an updated ownership filing showing that Nantahala Capital Management, LLC, together with Wilmot B. Harkey and Daniel Mack, reported beneficial ownership of 3,143,154 shares of common stock as of December 31, 2025, representing 7.52% of the outstanding class.
This total includes 612,244 shares that may be acquired within sixty days through warrant exercises. The reporting persons have no sole voting or dispositive power but share voting and dispositive power over all reported shares, which are held in the ordinary course of business and not for the purpose of changing or influencing control.
L1 Capital Pty Ltd, as reporting person, disclosed large indirect purchases of Anteris Technologies Global Corp. common equity through funds it controls and manages. On 01/22/2026, investment funds managed by L1 Capital bought 5,000,000 shares of common stock at $5.75 per share, bringing their indirectly beneficially owned common shares to 13,219,814.
The filing also shows that on 10/28/2025, these funds purchased 1,333,334 CHESS Depository Interests at $4.935 each. Each CHESS Depository Interest represents one underlying share of Anteris common stock and is exchangeable for those shares within 60 days, giving exposure to the same number of underlying common shares.
L1 Capital Pty Ltd has filed an amended Schedule 13G reporting beneficial ownership of 13,219,814 shares of Anteris Technologies Global Corp. common stock, representing 13.6% of the outstanding shares. L1 Capital reports sole voting and dispositive power over these shares.
The position is held through multiple L1-branded funds that L1 Capital controls and manages. The filing amends a prior report that covered 8,219,814 shares and certifies that the securities are held without the purpose or effect of changing or influencing control of Anteris.
Medtronic plc, through its affiliate Covidien Group S.a.r.l., has acquired 15,652,173 shares of Anteris Technologies Global Corp. common stock, representing about 16.2% of the company. The shares were purchased in a private placement at $5.75 per share, for approximately $90 million funded from Covidien’s cash.
As part of the deal, Anteris granted Covidien registration rights for the resale of these shares and entered into an Investor Rights Agreement. Covidien receives a right to participate in certain future issuances, may appoint a non-voting board observer, and is subject to transfer restrictions and a customary standstill through May 22, 2027. The agreement also gives Covidien notice and negotiation rights if Anteris receives certain acquisition proposals.
Medtronic plc, as a 10% owner of Anteris Technologies Global Corp. (AVR), has filed an initial ownership report. The filing shows indirect beneficial ownership of 15,652,173 shares of common stock, which are held through Covidien Group S.a.r.l. rather than directly by Medtronic.
Anteris Technologies Global Corp. has a resale registration covering up to 9,103,796 shares of common stock that may be sold by existing stockholders under a prior Form S-1. This prospectus supplement adds information from recent current reports, including a new capital raise. The company entered into an underwritten public offering of 34,782,609 shares, plus an additional 5,217,391 shares sold under the underwriters’ option, at $5.75 per share, and a concurrent private placement of 15,652,173 shares at the same price to a Medtronic subsidiary. Combined gross proceeds from the offering and private placement are expected to be approximately $320 million, before fees and expenses. Anteris plans to use the cash to fund its DurAVR THV pivotal trial, expand manufacturing, support v2vmedtech research and development, and for working capital and general corporate purposes.
Anteris Technologies Global Corp. reported that Medtronic plc, through a wholly owned subsidiary, is making a strategic equity investment in the company. The investment is structured under a stock purchase agreement dated January 20, 2026 between Anteris and the Medtronic subsidiary.
On January 22, 2026, Anteris and Medtronic issued a joint press release about this transaction, which is furnished as Exhibit 99.1. The disclosure is provided under Regulation FD, meaning it is intended to share the same information with all market participants at the same time.
Anteris Technologies Global Corp. entered into an underwritten public offering and a concurrent private placement of its common stock. The company agreed to sell 34,782,609 shares in the offering at $5.75 per share, and granted underwriters a 30-day option for 5,217,391 additional shares, which was exercised in full. It also agreed to sell 15,652,173 shares at $5.75 per share in a private placement to Covidien Group S.à r.l., a wholly owned subsidiary of Medtronic plc.
The combined transactions are expected to generate approximately $320 million in gross proceeds before fees and expenses. Anteris plans to use the net proceeds, together with existing cash, to support its next stage of growth, including the global pivotal PARADIGM Trial for its DurAVR® Transcatheter Heart Valve, expansion of manufacturing capabilities, funding ongoing research and development for v2vmedtech, inc., and for working capital and other general corporate purposes.